Elicera Therapeutics Investor Relations Material
Latest events
Investor Update
Elicera Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Elicera Therapeutics
Access all reports
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The company focuses on developing next-generation cell and gene therapies aimed at treating cancer through immune-based approaches. Elicera's pipeline includes four main drug candidates, two of which are in the field of oncolytic viruses and two in CAR T-cell therapies. Their proprietary iTANK (ImmunoTherapies Activated with Nap for efficient Killing) platform is designed to enhance the efficacy of these therapies. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
ELIC
Country
🇸🇪 Sweden